Importer of Controlled Substances Application: PerkinElmer, Inc., 10475-10476 [2020-03620]
Download as PDF
<![CDATA[
10475
Federal Register / Vol. 85, No. 36 / Monday, February 24, 2020 / Notices
Drug
code
Controlled substance
Pentobarbital ............................................................................................................................................................................
Secobarbital .............................................................................................................................................................................
Glutethimide .............................................................................................................................................................................
Nabilone ...................................................................................................................................................................................
1-Phenylcyclohexylamine ........................................................................................................................................................
Phencyclidine ...........................................................................................................................................................................
4-Anilino-N-phenethyl-4-piperidine (ANPP) .............................................................................................................................
Phenylacetone .........................................................................................................................................................................
1-Piperidinocyclohexanecarbonitrile ........................................................................................................................................
Alphaprodine ............................................................................................................................................................................
Anileridine ................................................................................................................................................................................
Cocaine ....................................................................................................................................................................................
Codeine ...................................................................................................................................................................................
Etorphine HCl ..........................................................................................................................................................................
Dihydrocodeine ........................................................................................................................................................................
Oxycodone ...............................................................................................................................................................................
Hydromorphone .......................................................................................................................................................................
Diphenoxylate ..........................................................................................................................................................................
Ecgonine ..................................................................................................................................................................................
Ethylmorphine ..........................................................................................................................................................................
Hydrocodone ...........................................................................................................................................................................
Levomethorphan ......................................................................................................................................................................
Levorphanol .............................................................................................................................................................................
Isomethadone ..........................................................................................................................................................................
Meperidine ...............................................................................................................................................................................
Meperidine intermediate-A ......................................................................................................................................................
Meperidine intermediate-B ......................................................................................................................................................
Meperidine intermediate-C ......................................................................................................................................................
Metazocine ..............................................................................................................................................................................
Methadone ...............................................................................................................................................................................
Methadone intermediate ..........................................................................................................................................................
Metopon ...................................................................................................................................................................................
Dextropropoxyphene, bulk (non-dosage forms) ......................................................................................................................
Morphine ..................................................................................................................................................................................
Oripavine .................................................................................................................................................................................
Thebaine ..................................................................................................................................................................................
Dihydroetorphine .....................................................................................................................................................................
Levo-alphacetylmethadol .........................................................................................................................................................
Oxymorphone ..........................................................................................................................................................................
Noroxymorphone .....................................................................................................................................................................
Phenazocine ............................................................................................................................................................................
Thiafentanil ..............................................................................................................................................................................
Piminodine ...............................................................................................................................................................................
Racemethorphan .....................................................................................................................................................................
Racemorphan ..........................................................................................................................................................................
Alfentanil ..................................................................................................................................................................................
Remifentanil .............................................................................................................................................................................
Sufentanil .................................................................................................................................................................................
Carfentanil ...............................................................................................................................................................................
Tapentadol ...............................................................................................................................................................................
Bezitramide ..............................................................................................................................................................................
Fentanyl ...................................................................................................................................................................................
Moramide-intermediate ............................................................................................................................................................
The company plans to manufacture
small quantities of the listed controlled
substances in bulk for distribution to its
customers.
lotter on DSKBCFDHB2PROD with NOTICES
Dated: February 3, 2020.
William T. McDermott,
Assistant Administrator.
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–589]
[FR Doc. 2020–03612 Filed 2–21–20; 8:45 am]
ACTION:
Notice of application.
BILLING CODE 4410–09–P
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
DATES:
VerDate Sep<11>2014
18:30 Feb 21, 2020
Jkt 250001
PO 00000
Frm 00078
Fmt 4703
Sfmt 4703
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
or before March 25, 2020. Such persons
may also file a written request for a
hearing on the application on or before
March 25, 2020.
Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing must
be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All requests for a
hearing should also be sent to: (1) Drug
ADDRESSES:
Importer of Controlled Substances
Application: PerkinElmer, Inc.
2270
2315
2550
7379
7460
7471
8333
8501
8603
9010
9020
9041
9050
9059
9120
9143
9150
9170
9180
9190
9193
9210
9220
9226
9230
9232
9233
9234
9240
9250
9254
9260
9273
9300
9330
9333
9334
9648
9652
9668
9715
9729
9730
9732
9733
9737
9739
9740
9743
9780
9800
9801
9802
Schedule
E:\FR\FM\24FEN1.SGM
24FEN1
10476
Federal Register / Vol. 85, No. 36 / Monday, February 24, 2020 / Notices
Enforcement Administration, Attn:
Hearing Clerk/OALJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DPW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.34(a), this
is notice that on January 13, 2020,
PerkinElmer, Inc., 120 E Dedham Street,
Boston, Massachusetts 02118–2852
applied to be registered as an importer
of the following basic classes of
controlled substances:
Controlled substance
Drug code
Lysergic acid diethylamide ..............................................................................................................................................
Thebaine ..........................................................................................................................................................................
The company plans to import the
listed controlled substances in bulk for
manufacturing wherein the controlled
substances will be labeled with a
radioactive tracer compound and sold
for research purposes to its customers.
Thebaine (9333) will be used to
manufacture the derivative
Diprenorphine.
Dated: January 31, 2020.
William T. McDermott,
Assistant Administrator.
[FR Doc. 2020–03620 Filed 2–21–20; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
[OMB Number 1190–0008]
Agency Information Collection
Activities, Proposed eCollection
eComments Requested Extension
Without Change, of a Previously
Approved Collection; Federal
Coordination and Compliance Section
(FCS); FCS Complaint and Consent
Form
Civil Rights Division,
Department of Justice.
ACTION: 30-Day notice.
AGENCY:
The Department of Justice
(DOJ), Civil Rights Division, Federal
Coordination and Compliance Section,
will be submitting the following
information collection request to the
Office of Management and Budget
(OMB) for review and approval in
accordance with the Paperwork
Reduction Act of 1995.
DATES: The Department of Justice
encourages public comment and will
accept input until March 25, 2020.
FOR FURTHER INFORMATION CONTACT: If
you have additional comments
especially on the estimated public
burden or associated response time,
suggestions, or need a copy of the
proposed information collection
instrument with instructions or
additional information, please contact
Christine Stoneman, Acting Chief,
Federal Coordination and Compliance
Section, 950 Pennsylvania Avenue NW–
lotter on DSKBCFDHB2PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
18:30 Feb 21, 2020
Jkt 250001
4CON, Washington, DC 20002 (phone:
202–307–2222).
SUPPLEMENTARY INFORMATION: Written
comments and suggestions from the
public and affected agencies concerning
the proposed collection of information
are encouraged. Your comments should
address one or more of the following
four points:
—Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
—Evaluate the accuracy of the agency’s
estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
—Enhance the quality, utility, and
clarity of the information to be
collected; and
—Minimize the burden of the collection
of information on those who are to
respond, including through the use of
appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms
of information technology, e.g.,
permitting electronic submission of
responses.
Overview of This Information
Collection
1. Type of Information Collection:
Extension of a currently approved
collection.
2. The Title of the Form/Collection:
Complaint and Consent Form.
3. The agency form number, if any,
and the applicable component of the
Department sponsoring the collection:
The form number is 1190–0008. The
applicable component within the
Department of Justice is the Federal
Coordination and Compliance Section,
in the Civil Rights Division.
4. Affected public who will be asked
or required to respond, as well as a brief
abstract: General public.
Information is used to find
jurisdiction to investigate the alleged
discrimination, to seek whether a
referral to another agency is necessary
and to provide information needed to
PO 00000
Frm 00079
Fmt 4703
Sfmt 4703
7315
9333
Schedule
I
II
initiate investigation of the complaint.
Respondents are individuals.
5. An estimate of the total number of
respondents and the amount of time
estimated for an average respondent to
respond: It is estimated that 4000
respondents will complete each form
within approximately 30 minutes.
6. An estimate of the total public
burden (in hours) associated with the
collection: There are an estimated 2000
total annual burden hours associated
with this collection.
If additional information is required
contact: Melody Braswell, Department
Clearance Officer, United States
Department of Justice, Justice
Management Division, Policy and
Planning Staff, Two Constitution
Square, 145 N Street NE, Room
3E.405A, Washington, DC 20530.
Dated: February 18, 2020.
Melody Braswell,
Department Clearance Officer for PRA, U.S.
Department of Justice.
[FR Doc. 2020–03544 Filed 2–21–20; 8:45 am]
BILLING CODE 4410–13–P
DEPARTMENT OF JUSTICE
[OMB Number 1122–0034]
Agency Information Collection
Activities; Proposed eCollection
eComments Requested; Extension of a
Currently Approved Collection
Office on Violence Against
Women, Department of Justice.
ACTION: 60-Day notice.
AGENCY:
The Department of Justice,
Office on Violence Against Women
(OVW) will be submitting the following
information collection request to the
Office of Management and Budget
(OMB) for review and approval in
accordance with the Paperwork
Reduction Act of 1995.
DATES: Comments are encouraged and
will be accepted for 60 days until April
24, 2020.
FOR FURTHER INFORMATION CONTACT:
Written comments and/or suggestion
regarding the items contained in this
notice, especially the estimated public
SUMMARY:
E:\FR\FM\24FEN1.SGM
24FEN1
]]>Agencies
[Federal Register Volume 85, Number 36 (Monday, February 24, 2020)]
[Notices]
[Pages 10475-10476]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-03620]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-589]
Importer of Controlled Substances Application: PerkinElmer, Inc.
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturers of the affected basic classes, and
applicants therefore, may file written comments on or objections to the
issuance of the proposed registration on or before March 25, 2020. Such
persons may also file a written request for a hearing on the
application on or before March 25, 2020.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DPW,
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a
hearing must be sent to: Drug Enforcement Administration, Attn:
Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All
requests for a hearing should also be sent to: (1) Drug
[[Page 10476]]
Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and (2) Drug Enforcement
Administration, Attn: DEA Federal Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this
is notice that on January 13, 2020, PerkinElmer, Inc., 120 E Dedham
Street, Boston, Massachusetts 02118-2852 applied to be registered as an
importer of the following basic classes of controlled substances:
------------------------------------------------------------------------
Controlled substance Drug code Schedule
------------------------------------------------------------------------
Lysergic acid diethylamide......... 7315 I
Thebaine........................... 9333 II
------------------------------------------------------------------------
The company plans to import the listed controlled substances in
bulk for manufacturing wherein the controlled substances will be
labeled with a radioactive tracer compound and sold for research
purposes to its customers. Thebaine (9333) will be used to manufacture
the derivative Diprenorphine.
Dated: January 31, 2020.
William T. McDermott,
Assistant Administrator.
[FR Doc. 2020-03620 Filed 2-21-20; 8:45 am]
BILLING CODE 4410-09-P
